Lenalidomide may stave off multiple myeloma
However, its toxicity may limit the drug's use
Lenalidomide cuts the risk of smouldering multiple myeloma progressing to overt cancer, a randomised controlled phase II/III trial has shown.
The study of patients with intermediate or high-risk smouldering multiple myeloma, a precancerous condition, found that three-year progression-free survival was 87% in phase II and 91% in phase III among patients receiving lenalidomide compared with 66% among those who did not receive the therapy and were just observed.
